Hui Xin Ong, Daniela Traini, Paul M Young
Inhalation of liposomes formulated with phospholipids similar to endogenous lung surfactants and lipids offers biocompatibility and versatility within the pulmonary medicine field to treat a range of diseases such as lung cancer, cystic fibrosis and lung infections. Manipulation of the physicochemical properties of liposomes enables innovative design of the carrier to meet specific delivery, release and targeting requirements. This delivery system offers several benefits: improved pharmacokinetics with reduced toxicity, enhanced therapeutic efficacy, increased delivery of poorly soluble drugs, taste masking, biopharmaceutics degradation protection and targeted cellular therapy...
April 2024: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Mingyu Meng, Xiaoxia Liu, Xueyan Liang, Xiaoyu Chen, Yan Li
BACKGROUND: Durvalumab plus etoposide-platinum (DEP) showed sustained overall survival improvements in patients with extensive-stage small-cell lung cancer (ES-SCLC) compared to etoposide-platinum (EP), but adding tremelimumab to DEP (DTEP) did not significantly improve outcomes. A third-party payer perspective is taken here to evaluate the cost-effectiveness of DTEP, DEP, and EP for ES-SCLC. METHODS: The cost-effectiveness was evaluated by partitioning survival models into 3 mutually exclusive health states...
April 19, 2024: Medicine (Baltimore)
Yong Li, Huiqin Huang, Xiangli Ye, Bangwei Zeng, Feijian Huang, Limin Chen
Immune checkpoint inhibitor pneumonitis (ICIP) is thought to be a self-limiting disease; however, an effective treatment option does not currently exist. This study aimed to determine the clinical efficacy of combination therapy with glucocorticoids and pirfenidone for ICIP related to programmed cell death protein-1 (PD-1) inhibitors. We conducted a retrospective analysis of 45 patients with advanced non-small cell lung cancer who developed ICIP following PD-1 inhibitor and albumin-bound paclitaxel or carboplatin treatment at our hospital...
April 19, 2024: Medicine (Baltimore)
Siqi Zhang, Liangwei Yang, Weiwen Xu, Yue Wang, Liyuan Han, Guofang Zhao, Ting Cai
In response to the high incidence and poor prognosis of lung cancer, this study tends to develop a generalizable lung-cancer prediction model by using machine learning to define high-risk groups and realize the early identification and prevention of lung cancer. We included 467,888 participants from UK Biobank, using lung cancer incidence as an outcome variable, including 49 previously known high-risk factors and less studied or unstudied predictors. We developed multivariate prediction models using multiple machine learning models, namely logistic regression, naïve Bayes, random forest, and extreme gradient boosting models...
April 19, 2024: Medicine (Baltimore)
Jie Jin, Yumeng Cui, Huicong Niu, Yanli Lin, Xiaojie Wu, Xuejiao Qi, Kaixuan Bai, Yu Zhang, Youliang Wang, Hui Bu
Leptomeningeal metastasis (LM) is a devastating complication of advanced non-small cell lung cancer (NSCLC). Diagnosis and monitoring of LM can be challenging. Extracellular vesicles (EVs) microRNAs (miRNAs) have become a new noninvasive diagnostic biomarker. The purpose of this study was to examine the clinical value and role of EVs miRNAs in NSCLC-LM. According to next-generation sequencing (NGS), miRNAs with differential expression of EVs in serum of NSCLC patients with LM and non-LM were detected to find biological markers for the diagnosis of LM...
April 19, 2024: Molecular Cancer Research: MCR
Maedeh Mashhadbani, Edris Faizabadi
In this research, we explore the impact of edge passivation using halogen atoms on armchair stanene nanoribbon (ASNR) for the early detection of lung cancer biomarkers. We employ non-equilibrium green function (NEGF) and density functional theory (DFT) methods to evaluate sensing characteristics. The edges of ASNR are passivated with fluorine, chlorine, bromine, and iodine atoms. Our findings indicate a significant enhancement in sensing performance upon halogenation of ASNR. Notable changes in adsorption energy and current for edge-halogenated ASNR configurations demonstrate improved sensing behavior...
April 19, 2024: Physical Chemistry Chemical Physics: PCCP
Eliseu Becco Neto, Dhiego Chaves de Almeida Bastos, Marcia Harumy Yoshikawa, Eberval Gadelha Figueiredo, Francisco de Assis de Souza Filho, Sujit Prabhu
Stereotactic radiosurgery (SRS) is an option for brain metastases (BM) not eligible for surgical resection, however, predictors of SRS outcomes are poorly known. The aim of this study is to investigate predictors of SRS outcome in patients with BM secondary to non-small cell lung cancer (NSCLC). The secondary objective is to analyze the value of volumetric criteria in identifying BM progression. This retrospective cohort study included patients >18 years of age with a single untreated BM secondary to NSCLC...
April 19, 2024: Neurosurgical Review
Fumio Kasai, Makoto Fukushima, Yohei Miyagi, Yukio Nakamura
Japan is often assumed to have a highly homogeneous ethnic population, because it is an island country. This is evident in human cell lines collected from cell banks; however, these genotypes have not been thoroughly characterized. To examine the population genotypes of human cell lines established in Japan, we conducted SNP genotyping on 57 noncancerous cell lines and 43 lung cancer cell lines. Analysis of biogeographic ancestry revealed that 58 cell lines had non-admixed Japanese genotypes, 21 cell lines had an admixture of Japanese and East Asian genotypes, and the remaining 21 cell lines had East Asian genotypes...
April 19, 2024: Human Cell
Tukaram Kedar, Sunil Jalalpure, Bhaskar Kurangi
Aim: To prepare fisetin (FIS) cubosomal nanoformulation to increase aqueous solubility and anticancer activity. Methods: Top-down method using glyceryl monooleate (GMO) and Pluronic F-127. Results: Optimized using 2% GMO and 1% Pluronic F-127, reported 93.07 nm particle size, 80.10% drug entrapment, and reports more than 50% enhanced in vitro drug release than native FIS. MTT assay reports IC50 Values of FIS 16.59 μg/ml and optimized cubosomal FIS nanoformulation (FISCUB) 12.18 μg/ml...
April 19, 2024: Therapeutic Delivery
Jin-Shu Fang, Jian-Yi Huang, Liu Li, Ping-Ping Zhai, Mian-Hua Wu, Wen-Ting Li
OBJECTIVE: Network pharmacology is an emerging discipline that applies computational methods to understand drug actions and interactions with multiple molecular targets. Xiao'ai Jiedu is a valued traditional Chinese medicine preparation for which the mechanism of action is not yet established. This study aims to explore the mechanism of Xiao'ai Jiedu in treating lung cancer through network pharmacology. METHODS: First, the Traditional Chinese Medicine Systems Pharmacology (TCMSP) data platform was used to analyze the target treatment results of different medicinal materials in Mr...
April 18, 2024: Alternative Therapies in Health and Medicine
Tetyana Bagnyukova, Brian L Egleston, Valerii A Pavlov, Ilya G Serebriiskii, Erica A Golemis, Hossein Borghaei
The most common oncogenic driver mutations for non-small cell lung cancer (NSCLC) activate the epidermal growth factor receptor (EGFR) or KRAS. Clinical trials exploring treatments for EGFR- or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials...
April 19, 2024: Cancer Res Commun
Bo Pan, Yanming Wang, Zehua Zhu, Xingxing Zhu
PURPOSE: Pulmonary inflammatory pseudotumor (PIP) is an inflammatory proliferative tumor-like lesion that frequently exhibits hypermetabolism on 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography imaging (PET/CT) and is readily misdiagnosed as a malignant tumor. The purpose of this study was to identify PIP by combining PET/computed tomography metabolic and blood test characteristics with machine learning. PATIENTS AND METHODS: We recruited 27 patients with PIP and 28 patients with lung cancer (LC)...
April 18, 2024: Journal of Thoracic Imaging
Feifeng Song, Zhentao Zhang, Weifeng Liu, Tong Xu, Xiaoping Hu, Qiyue Wang, Wanli Zhang, Luqi Ge, Chengwu Zhang, Qing Hu, Hui Qin, Song Zhang, Xinxin Ren, Weijiao Fan, Yiwen Zhang, Ping Huang
Cancer metastasis is the leading cause of mortality in patients with hepatocellular carcinoma (HCC). To meet the rapid malignant growth and transformation, tumor cells dramatically increase the consumption of nutrients, such as amino acids. Peptide transporter 1 (PEPT1), a key transporter for small peptides, has been found to be an effective and energy-saving intracellular source of amino acids that are required for the growth of tumor cells. Here, the role of PEPT1 in HCC metastasis and its underlying mechanisms is explored...
April 19, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
Yanzheng Wang, Jiahui Zhang, Hui Shi, Maoye Wang, Dan Yu, Min Fu, Yu Qian, Xiaoxin Zhang, Runbi Ji, Shouyu Wang, Jianmei Gu, Xu Zhang
M2-polarized tumor-associated macrophages (M2 TAMs) promote cancer progression. Exosomes mediate cellular communication in the tumor microenvironment (TME). However, the roles of exosomes from M2 TAMs in gastric cancer progression are unclear. Herein, it is reported that M2 TAMs-derived exosomes induced aerobic glycolysis in gastric cancer cells and enhanced their proliferation, metastasis, and chemoresistance in a glycolysis-dependent manner. It is identified that MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is enriched in M2 TAM exosomes and confirmed that MALAT1 transfer from M2 TAMs to gastric cancer cells via exosomes mediates this effect...
April 19, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
Yingjie Gao, Guangliang Zhang, Jinlong Liu, Huimin Li
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the immunohistochemical data shown in Fig. 1A on p. 5, colony formation data shown in Figs. 2C, H and M and 6D on p. 6 and p. 10 respectively, the western blots in Fig. 2B, Transwell cell migration and invasion assay data in Fig. 3B, D and F, and immunofluorescence data in Fig. 4C had already appeared in previously published articles written by different authors at different research institutes (some of which have subsequently been retracted)...
June 2024: Oncology Reports
Junhui Ye, Wujun Luo, Lingling Luo, Limin Zhai, Pingping Huang
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the western blotting data shown in Fig. 4B and the Transwell cell invasion data shown in Figs. 2D and 4E were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had already been published elsewhere prior to the submission of this paper to Molecular Medicine Reports (one of which has been retracted). Moreover, there appeared to be inappropriately edited western blot bands featured in Figs...
June 2024: Molecular Medicine Reports
Michele Massimo Gulizia, Fabio Maria Turazza, Pietro Ameri, Marco Alings, Ronan Collins, Leonardo De Luca, Marcello Di Nisio, Donata Lucci, Domenico Gabrielli, Stefan Janssens, Iris Parrini, Fausto J Pinto, Jose Luis Zamorano, Furio Colivicchi
BACKGROUND: Cancer is an important condition associated with the development of atrial fibrillation (AF). The objectives of the BLITZ-AF Cancer study were to collect real-life information on the clinical profile and use of antithrombotic drugs in patients with AF and cancer to improve clinical management, as well as the evaluation of the association between different antithrombotic treatments (or their absence) and the main clinical events. METHODS: European multinational, multicenter, prospective, non-interventional study conducted in patients with AF (electrocardiographically confirmed) and cancer occurring within 3 years...
May 2024: Giornale Italiano di Cardiologia
Xuran Chu, Vahid Kheirollahi, Arun Lingampally, Prakash Chelladurai, Chanil Valasarajan, Ana Ivonne Vazquez-Armendariz, Stefan Hadzic, Ali Khadim, Oleg Pak, Stefano Rivetti, Jochen Wilhelm, Marek Bartkuhn, Slaven Crnkovic, Alena Moiseenko, Monika Heiner, Simone Kraut, Leila Sotoodeh, Janine Koepke, Guilherme Valente, Clemens Ruppert, Thomas Braun, Christos Samakovlis, Ioannis Alexopoulos, Mario Looso, Cho-Ming Chao, Susanne Herold, Werner Seeger, Grazyna Kwapiszewska, Xiaoying Huang, Jin-San Zhang, Soni Savai Pullamsetti, Norbert Weissmann, Xiaokun Li, Elie El Agha, Saverio Bellusci
BACKGROUND: The precise origin of newly formed ACTA2+ (alpha smooth muscle actin-positive) cells appearing in nonmuscularized vessels in the context of pulmonary hypertension is still debatable although it is believed that they predominantly derive from preexisting vascular smooth muscle cells (VSMCs). METHODS: Gli1 Cre-ERT2 ; tdTomato flox mice were used to lineage trace GLI1+ (glioma-associated oncogene homolog 1-positive) cells in the context of pulmonary hypertension using 2 independent models of vascular remodeling and reverse remodeling: hypoxia and cigarette smoke exposure...
April 19, 2024: Circulation Research
Chao Li, Richard A Preston, Emily Dumas, Andrew Beelen, Thomas C Marbury
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of trilaciclib...
April 19, 2024: Journal of Clinical Pharmacology
Zhedong Zhang, Yu Huang, Haihua Gu, Lufeng Zhao, Baiqin Zhao
The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). p. G719X and p. S768I mutations, often present in the form of complex mutations, are considered rare. This study firstly reported the treatment outcome of a locally advanced unresectable NSCLC patient with a rare complex EGFR p. G719X/ p. S768I mutations who received befotertinib...
2024: Frontiers in Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.